Ulcerative Colitis

Oliva-Hemker M, Escher JC, Moore D, Dubinksy M, Hildebrand H, Koda YK, Murch S, Sandhu B, Seo JK, Tanzi MN, Warner B, Anonymous00097. · Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD 21287-2631, USA. · J Pediatr Gastroenterol Nutr. · Pubmed #18664886 No free full text.

This publication has no abstract.

Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. · Department of Dermatology, Academic Medical Center, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands. · Br J Dermatol. · Pubmed #18627374 No free full text.

Abstract: Infliximab (Remicade; Schering-Plough, Kenilworth, NJ, U.S.A.) is a chimeric monoclonal antibody that acts as a tumour necrosis factor-alpha inhibitor. Infliximab is registered for the treatment of rheumatoid arthritis, psoriatic arthritis, Crohn disease, ulcerative colitis, ankylosing spondylitis and plaque-type psoriasis. Like other foreign protein-derived agents, infliximab may lead to infusion reactions during and after infusion. Infusion reactions occur in 3-22% of patients with psoriasis treated with infliximab. Most of these reactions are mild or moderate and only few are severe. Nevertheless, they may lead to discontinuation of treatment. As infliximab for psoriasis is prescribed as a last resort and is in most cases very effective, discontinuation of treatment is undesirable. With proper care and prevention of the infusion reactions the need to discontinue treatment with infliximab can be diminished. The objective of this article is to present a guideline for the management of infliximab-related infusion reactions, based on the best available evidence. This guideline can be used in patients with psoriasis as well as in dermatology patients receiving infliximab for off-label indications such as hidradenitis suppurativa or pyoderma gangrenosum.

Anonymous00018, Anonymous00019, Ouyang Q, Hu PJ, Qian JM, Zheng JJ, Hu RW. · Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China. · J Dig Dis. · Pubmed #18251795 No free full text.

This publication has no abstract.

Anonymous00234. · No affiliation provided · J Gastrointest Surg. · Pubmed #18062071 No free full text.

This publication has no abstract.

Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schütz T, van Gemert W, van Gossum A, Valentini L, Anonymous00249, Lübke H, Bischoff S, Engelmann N, Thul P, Anonymous00250. · Department of Gastroenterology, Charité-Universitätsmedizin, CCM, Berlin, Germany. · Clin Nutr. · Pubmed #16698129 No free full text.

Abstract: Undernutrition as well as specific nutrient deficiencies have been described in patients with Crohn's disease (CD), ulcerative colitis (UC) and short bowel syndrome (SBS). The present guideline gives evidence-based recommendations for the indication, application and type of formula of enteral nutrition (EN) (oral nutritional supplements (ONS) or tube feeding (TF)) in these patients. It was developed in an interdisciplinary consensus-based process in accordance with officially accepted standards and is based on all relevant publications since 1985. ONS and/or TF in addition to normal food is indicated in undernourished patients with CD or CU to improve nutritional status. In active CD EN is the first line therapy in children and should be used as sole therapy in adults mainly when treatment with corticosteroids is not feasible. No significant differences have been shown in the effects of free amino acid, peptide-based and whole protein formulae for TF. In remission ONS is recommended only in steroid dependent patients in CD. In patients with SBS TF should be introduced in the adaptation phase and should be changed with progressing adaptation to ONS in addition to normal food.

Cohen JL, Strong SA, Hyman NH, Buie WD, Dunn GD, Ko CY, Fleshner PR, Stahl TJ, Kim DG, Bastawrous AL, Perry WB, Cataldo PA, Rafferty JF, Ellis CN, Rakinic J, Gregorcyk S, Shellito PC, Kilkenny JW, Ternent CA, Koltun W, Tjandra JJ, Orsay CP, Whiteford MH, Penzer JR, Anonymous00320. · Fletcher Allen Health Care, 111 Colchester Avenue, Fletcher 301, Burlington, Vermont 05401, USA. · Dis Colon Rectum. · Pubmed #16258712 No free full text.

Abstract: The American Society of Colon and Rectal Surgeons is dedicated to assuring high-quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The Standards Committee is composed of Society members who are chosen because they have demonstrated expertise in the specialty of colon and rectal surgery. This committee was created to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus. This is accompanied by developing Clinical Practice Guidelines based on the best available evidence. These guidelines are inclusive, and not prescriptive. Their purpose is to provide information on which decisions can be made, rather than dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, health care workers, and patients who desire information about the management of the conditions addressed by the topics covered in these guidelines. It should be recognized that these guidelines should not be deemed inclusive of all proper methods of care or exclusive of methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the propriety of any specific procedure must be made by the physician in light of all of the circumstances presented by the individual patient.

Anonymous00089. · No affiliation provided · J Pediatr Gastroenterol Nutr. · Pubmed #15990620 No free full text.

Abstract: Ulcerative colitis and Crohn disease may present before the age of 20 years in 25% to 30% of all patients with inflammatory bowel disease. Reported incidence figures vary considerably depending on the collection of data. Multicenter, multinational collaboration is needed when studying pediatric inflammatory bowel disease. The essential first step is uniformity in the work-up and criteria used for diagnosis. The Porto diagnostic criteria presented here provide the tool that is needed. These criteria are the result of consensus reached by the ESPGHAN inflammatory bowel disease working group. Diagnosis of Crohn disease, ulcerative colitis and indeterminate colitis is based on clinical signs and symptoms, endoscopy and histology and radiology. Every child suspected of inflammatory bowel disease should undergo a complete diagnostic program consisting of colonoscopy with ileal intubation, upper gastrointestinal endoscopy and (in all cases except in definite ulcerative colitis) radiologic contrast imaging of the small bowel. Multiple biopsies from all segments of the gastrointestinal tract are needed for a complete histologic evaluation. A diagnosis of indeterminate colitis cannot be made unless a full diagnostic program has been performed.

Marteau P, Seksik P, Beaugerie L, Bouhnik Y, Reimund JM, Gambiez L, Flourié B, Godeberge P. · Service d'hépato-gastroentérologie, Hôpital Européen Georges Pompidou, 75015 Paris. · Gastroenterol Clin Biol. · Pubmed #15672566 No free full text.

This publication has no abstract.

Hoffmann JC, Zeitz M, Anonymous00195. · Medizinische Klinik I mit Schwerpunkt Gastroenterologie/Infektiologie/Rheumatologie Charité, Universitätsmedizin Berlin Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin. · Med Klin (Munich). · Pubmed #15654542 No free full text.

This publication has no abstract.

Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, Orenstein W. · Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. · Inflamm Bowel Dis. · Pubmed #15472534 No free full text.

Abstract: During the past 2 decades, medical therapy for Crohn's disease (CD) and ulcerative colitis (UC) has grown to incorporate a variety of immunesuppressing agents. At the same time, basic insights into the aberrant mucosal immune response underlying inflammatory bowel disease (IBD) have expanded dramatically. The interplay of host susceptibility to infection and the safety and efficacy of immunization for vaccine-preventable diseases has been explored in other immune-mediated disease states but only rarely in IBD. The purpose of this review is to formulate best-practice recommendations for immunization in children and adults with IBD by considering the effects of the IBD disease state and its treatments on both the safety and efficacy of immunization. To do so, we first considered the routine recommendations for immunization of children, adults and distinct populations at increased risk for vaccine-preventable disease. Because it was rarely possible to examine direct data on safety and efficacy of immunization in IBD populations, we relied to a large extent upon extrapolation from similar populations and from knowledge of basic mechanisms. The literature suggests that efficacy of immunization may be diminished in some patients whose immune status is compromised by immune suppression. However, except for live agent vaccines, most immunizations may be safely administered to patients with IBD even when immune compromised. Conversely, protection against vaccine-preventable illness may be of even greater benefit to those at risk for morbid or lethal complications of infections because of an immune compromised state. We conclude that for most patients with IBD, recommendations for immunization do not deviate from recommended schedules for the general population.

Tomomasa T, Kobayashi A, Ushijima K, Uchida K, Kagimoto S, Shimizu T, Tajiri H, Tahara T, Yoden A, Anonymous00348. · Department of Pediatrics, Gunma University Graduate School, Japan. · Pediatr Int. · Pubmed #15310325 No free full text.

Abstract: This paper introduces the guidelines for treatment of ulcerative colitis in children, created by the working group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (Chair: Yuichiro Yamashiro) and the Japanese Society for Pediatric Inflammatory Bowel Disease (IBD) (Chair: Akio Kobayashi). The ideas of the working group, with regard to the fundamental differences in medical treatment between children and adults, included: (1) for children, intensive medical treatment including appropriate systemic management is important during the acute phase of illness. (2) Treatment with steroids, which can cause growth disturbances, should not be continued for long periods of time. (3) Pulsed steroid therapy, selective removal of blood cells, and intravenous infusion of cyclosporin should be included in the therapeutic option for severe and fluminant cases.

Carter MJ, Lobo AJ, Travis SP, Anonymous00282. · Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK. · Gut. · Pubmed #15306569 links to  free full text

This publication has no abstract.

Kornbluth A, Sachar DB, Anonymous00314. · The Henry D. Janowitz Division of Gastroenterology, The Department of Medicine, Mount Sinai School of Medicine, The Mount Sinai Medical Center, New York, NY 10128, USA. · Am J Gastroenterol. · Pubmed #15233681 No free full text.

Abstract: Guidelines for clinical practice are intended to indicate preferred approaches to medical problems as established by scientifically valid research. Double-blind placebo-controlled studies are preferable, but compassionate use reports and expert review articles are utilized in a thorough review of the literature conducted through Medline with the National Library of Medicine. When only data that will not withstand objective scrutiny are available, a recommendation is identified as a consensus of experts. Guidelines are applicable to all physicians who address the subject without regard to the specialty training or interests and are intended to indicate the preferable but not necessarily the only acceptable approach to a specific problem. Guidelines are intended to be flexible and must be distinguished from standards of care, which are inflexible and rarely violated. Given the wide range of specifics in any health-care problem, the physician must always choose the course best suited to the individual patient and the variables in existence at the moment of decision. Guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and approved by the Board of Trustees. Each has been extensively reviewed and revised by the Committee, other experts in the field, physicians who will use them, and specialists in the science of decision of analysis. The recommendations of each guideline are therefore considered valid at the time of their production based on the data available. New developments in medical research and practice pertinent to each guideline will be reviewed at a time established and indicated at the publication in order to assure continued validity.

Matthes H, Anonymous00111. · No affiliation provided · Z Gastroenterol. · Pubmed #12541175 No free full text.

This publication has no abstract.

Obrador A, López San Román A, Muñoz P, Fortún J, Gassull MA, Anonymous00002. · Servicio de Digestivo. Hospital Son Dureta. Palma de Mallorca. España. · Gastroenterol Hepatol. · Pubmed #12525326 No free full text.

This publication has no abstract.

Anonymous00195. · No affiliation provided · Z Gastroenterol. · Pubmed #11217687 No free full text.

This publication has no abstract.

Moser G, Anonymous00194. · No affiliation provided · Z Gastroenterol. · Pubmed #11215371 No free full text.

This publication has no abstract.

Schreiber S, Anonymous00193. · No affiliation provided · Z Gastroenterol. · Pubmed #11215370 No free full text.

This publication has no abstract.

Bruch HP, Anonymous00191. · No affiliation provided · Z Gastroenterol. · Pubmed #11215368 No free full text.

This publication has no abstract.

Porschen R, Anonymous00190. · No affiliation provided · Z Gastroenterol. · Pubmed #11215367 No free full text.

This publication has no abstract.

Kruis W, Anonymous00189. · No affiliation provided · Z Gastroenterol. · Pubmed #11215365 No free full text.

This publication has no abstract.

Schölmerich J, Anonymous00188. · No affiliation provided · Z Gastroenterol. · Pubmed #11215364 No free full text.

This publication has no abstract.

Stange EF, Anonymous00187. · No affiliation provided · Z Gastroenterol. · Pubmed #11215363 No free full text.

This publication has no abstract.

Fleig WE, Anonymous00186. · No affiliation provided · Z Gastroenterol. · Pubmed #11215362 No free full text.

This publication has no abstract.

Lochs H, Anonymous00185. · No affiliation provided · Z Gastroenterol. · Pubmed #11215361 No free full text.

This publication has no abstract.